Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial
Abstract
Introduction Hypertension is the primary modifiable risk factor for cardiorenal complications of chronic kidney disease (CKD). It is well established that lowering blood pressure (BP) in patients with CKD reduces renal and cardiovascular complications. The guidelines advise starting the BP-lowering drug with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARB), but then there is no strong evidence to support the preferential use of any particular agent in controlling BP. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. Methods and analysis This is a two-parallel group cluster randomised superiority phase 3 trial comparing a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics to standard of care. The primary endpoint is a composite time-to-event endpoint of (1) kidney failure with replacement therapy (KFRT), (2) estimated glomerular filtration rate decline ≥40%, (3) cardiovascular events (myocardial infarction, heart failure hospitalisation, stroke) and (4) all-cause mortality. Secondary endpoints include each component of the primary endpoint, systolic and diastolic BP at 3 months and 6 months post baseline then every 6 months, proportion of patients with controlled BP at 2 years, change from baseline in glomerular filtration rate and in proteinuria (g/day) or proteinuria/creatininuria (g/g) at 3 months and 6 months post baseline then every 6 months, proportion of patients who used at least one diuretic, quality of life and safety. It is planned to include 720 patients in 40 centres. Ethics and dissemination This study was approved by the Ethics Committee CPP Ile-de-France VII on 23 January 2023 (ref: 2022–5 01 494-39-00). Study findings will be published in a peer-reviewed journal and presented at scientific conferences. Trial registration number NCT05732727 .
Related
- Comparative Efficacy of Treatments for Resistant or Uncontrolled Hypertension : A Network Meta-Analysis of Randomized Trials
- Factors associated with chronic kidney disease stage among patients with uncontrolled diabetes and/or hypertension in Northeastern Thailand: a cross-sectional study
- Non-aneurysmal perimesencephalic subarachnoid hemorrhage in a middle-aged female possibly triggered by Valsalva-like event and uncontrolled hypertension: a case report
- Baxdrostat for uncontrolled and resistant hypertension: are we ready to change clinical practice?
- The Effects of Poor Self‐Care Behaviors on Uncontrolled Hypertension in Ethiopia: A Systematic Review and Meta‐Analysis
BibTeX
@article{vilainabraham2026intensification,
title = {{Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial}},
author = {Floriane Le Vilain-Abraham and Jean-Michel Halimi and Patrick Rossignol and Maurice Laville and Michel Azizi and Bénédicte Stengel and Valentin Maisons and Agnès Rouzès and Agnès Caille and Bénédicte Sautenet},
journal = {BMJ Open},
year = {2026},
month = sep,
doi = {10.1136/bmjopen-2026-122192},
url = {https://hal.univ-lorraine.fr/hal-05758201v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial
AU - Floriane Le Vilain-Abraham
AU - Jean-Michel Halimi
AU - Patrick Rossignol
AU - Maurice Laville
AU - Michel Azizi
AU - Bénédicte Stengel
AU - Valentin Maisons
AU - Agnès Rouzès
AU - Agnès Caille
AU - Bénédicte Sautenet
PY - 2026
DA - 2026/09/17
JO - BMJ Open
DO - 10.1136/bmjopen-2026-122192
UR - https://hal.univ-lorraine.fr/hal-05758201v1
AB - Introduction Hypertension is the primary modifiable risk factor for cardiorenal complications of chronic kidney disease (CKD). It is well established that lowering blood pressure (BP) in patients with CKD reduces renal and cardiovascular complications. The guidelines advise starting the BP-lowering drug with ACE inhibitors (ACEi) or angiotensin receptor blockers (ARB), but then there is no strong evidence to support the preferential use of any particular agent in controlling BP. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. Methods and analysis This is a two-parallel group cluster randomised superiority phase 3 trial comparing a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics to standard of care. The primary endpoint is a composite time-to-event endpoint of (1) kidney failure with replacement therapy (KFRT), (2) estimated glomerular filtration rate decline ≥40%, (3) cardiovascular events (myocardial infarction, heart failure hospitalisation, stroke) and (4) all-cause mortality. Secondary endpoints include each component of the primary endpoint, systolic and diastolic BP at 3 months and 6 months post baseline then every 6 months, proportion of patients with controlled BP at 2 years, change from baseline in glomerular filtration rate and in proteinuria (g/day) or proteinuria/creatininuria (g/g) at 3 months and 6 months post baseline then every 6 months, proportion of patients who used at least one diuretic, quality of life and safety. It is planned to include 720 patients in 40 centres. Ethics and dissemination This study was approved by the Ethics Committee CPP Ile-de-France VII on 23 January 2023 (ref: 2022–5 01 494-39-00). Study findings will be published in a peer-reviewed journal and presented at scientific conferences. Trial registration number NCT05732727 .
SN - 2044-6055
ER -